These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price]. Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544 [No Abstract] [Full Text] [Related]
4. [GlaxoSmithKline again lowers prices of drugs for HIV/AIDS and malaria]. Krankenpfl J; 2002; 40(7-9):222-3. PubMed ID: 12514863 [No Abstract] [Full Text] [Related]
5. Glaxo drops drug prices, AIDS foundation drops suit. AIDS Policy Law; 2003 May; 18(10):6. PubMed ID: 12809097 [No Abstract] [Full Text] [Related]
6. GlaxoSmithKline, under pressure, cuts price of AIDS treatment for poor countries. Fleck F Bull World Health Organ; 2003; 81(6):469. PubMed ID: 12894339 [No Abstract] [Full Text] [Related]
7. [Glaxo Wellcome, Germany, spends 60.000 DM for African HIV projects in Uganda and Malawi]. Krankenpfl J; 1999 Dec; 37(12):479. PubMed ID: 10734858 [No Abstract] [Full Text] [Related]
8. Drug makers to cut prices for developing countries. AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655 [TBL] [Abstract][Full Text] [Related]
9. World Trade Organization still threatens supply of affordable AIDS drugs. Hagmann M Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300 [No Abstract] [Full Text] [Related]
10. Called to account. Aldhous P Nature; 2004 Jul; 430(6996):133. PubMed ID: 15241382 [No Abstract] [Full Text] [Related]
11. An unequal activism for an unequal epidemic? Selemogo M Dev World Bioeth; 2005 May; 5(2):153-68. PubMed ID: 15842724 [TBL] [Abstract][Full Text] [Related]
12. Companies reduce prices for HIV drugs in developing countries. Gottlieb S Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926 [TBL] [Abstract][Full Text] [Related]
13. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. Marseille E; Saba J; Muyingo S; Kahn JG AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976 [TBL] [Abstract][Full Text] [Related]
14. Thank God for rich women with mustaches. Friedman JH Med Health R I; 2001 Jul; 84(7):222-3. PubMed ID: 11482273 [No Abstract] [Full Text] [Related]
15. AIDS research. Drug trials without the drugs? Cohen J Science; 2003 May; 300(5623):1212-3. PubMed ID: 12764159 [No Abstract] [Full Text] [Related]
16. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain. James JS AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151 [TBL] [Abstract][Full Text] [Related]
17. Commentary: the reality of treating HIV and AIDS in poor countries. Sykes R BMJ; 2002 Jan; 324(7331):216-7. PubMed ID: 11831203 [No Abstract] [Full Text] [Related]
18. Embarrassed firms slash prices for AIDs drugs. Boseley S N Z Med J; 2001 Oct; 114(1141):440. PubMed ID: 11700768 [No Abstract] [Full Text] [Related]
19. Balancing pills and patents: intellectual property and the HIV/AIDS crisis. Nderitu T E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022 [No Abstract] [Full Text] [Related]
20. Therapies. The high cost of poverty. Cohen J Science; 2002 Jun; 296(5577):2324. PubMed ID: 12089424 [No Abstract] [Full Text] [Related] [Next] [New Search]